Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen's Q2 Revenues Drop Sharply

NEW YORK (GenomeWeb News) – WaferGen reported after the close of the market Monday that revenues for the second quarter slid nearly 10-fold year over year due to an "absence of sales" of its flagship real-time PCR platform.

For the three months ended June 30, the Fremont, Calif.-based firm posted revenues of $44,905, down from $431,894 a year ago, a drop that it attributed to the absence of sales of its SmartChip Real-time PCR Systems, as well as a decrease in sales of its Real-time PCR Chip panels and fee-for-service.

WaferGen posted a net loss of $9.2 million, or $.45 per share, for the second quarter, compared to a profit of $724,496, or $.02 per share, a year ago.

The firm's R&D costs rose 33 percent year over year to $2 million from $1.5 million due to expenses associated with the development of SmartChip products and services. Its SG&A costs shot up 81 percent to $2.9 million from $1.6 million, the result of additional staffing, activities related to the commercialization and sales of SmartChip products, consulting expenses, and fundraising activities.

During the quarter, the company took a non-cash charge of $13.2 million related to a $30.6 million private placement that it completed in June. It also saw a net loss from warrant derivative revaluations of $191,000 during the quarter, compared to a gain of $3.6 million a year ago, WaferGen said.

Alnoor Shivji, chairman and CEO of the company, said in a statement that the primary focus during the quarter was to secure funding for further commercialization of the SmartChip Real-Time PCR System, launched a year ago. Having achieved that with the $30.6 million private placement, "We will put this money to work … to expand the commercial team and generate additional applications and content for the SmartChip System," he said.

"With additional applications (genotyping) and enhancements to SmartChip panels … we can continue to enrich the transformative SmartChip System to address unmet needs in biomarker profiling validation, next-generation sequencing validation, disease research, drug development, personalized medicine and applied markets," Shivji added.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.